Latest On Clearside Biomedical, Inc (CLSD):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 18:03 EST | News | Clearside Biomedical GAAP EPS of -$0.15 misses by $0.01, revenue of $0.04M misses by $0.1M | N/A |  |
| 2023-05-11 18:03 EST | News | Clearside Biomedical, Inc. (CLSD) Q1 2023 Earnings Call Transcript | N/A | |
| 2023-03-10 06:19 EST | News | Clearside Biomedical GAAP EPS of -$0.16 misses by $0.04, revenue of $0.3M beats by $0.2M | N/A | |
| 2023-03-10 06:19 EST | News | Clearside Biomedical, Inc. (CLSD) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-02-02 16:37 EST | News | Clearside gains 12% as eye disease therapy cuts need for additional treatment | N/A | |
About Clearside Biomedical, Inc (CLSD):
Clearside Biomedical, Inc., a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
General
- Name Clearside Biomedical, Inc
- Symbol CLSD
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Fiscal Year EndDecember
- IPO Date2016-06-02
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.clearsidebio.com
Valuation
- Price/Sales (Trailing 12 Mt.) 16.44
- Price/Book (Most Recent Quarter) 18.28
- Enterprise Value Revenue 18.36
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.30
- Next Year EPS Estimate -$0.41
- Next Quarter EPS Estimate -$0.08
- Profit Margin -231%
- Operating Margin -227%
- Return on Assets -49%
- Return on Equity -183%
- Revenue 7.89 million
- Earnings Per Share -$1.96
- Revenue Per Share $0.17
- Gross Profit 7.89 million
- Quarterly Earnings Growth -99.4%
Highlights
- Market Capitalization 161.93 million
- EBITDA -68909000
- PE Ratio -2.26
- Analyst Target Price $6.38
- Book Value Per Share $0.17
Share Statistics
- Shares Outstanding 57.42 million
- Shares Float 41.76 million
- % Held by Insiders 830%
- % Held by Institutions 41.37%
- Shares Short 428692
- Shares Short Prior Month 515638
- Short Ratio 0.75
- Short % of Float 1%
- Short % of Shares Outstanding 1%
Technicals
- Beta 1.42
- 52 Week High $4.53
- 52 Week Low $1.25
- 50 Day Moving Average 3.42
- 200 Day Moving Average 2.38
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
Clearside Biomedical, Inc (CLSD) Dividend Calendar:
Clearside Biomedical, Inc (CLSD) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
Clearside Biomedical, Inc (CLSD) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | N/A | N/A | 3.81 million | 1.31 million |
| Income Before Tax | N/A | N/A | N/A | -2.91 million | -3.1 million |
| Selling General Administrative | N/A | N/A | N/A | 3.12 million | 3.65 million |
| Gross Profit | N/A | N/A | N/A | N/A | 1.94 million |
| Ebit | N/A | N/A | N/A | -2.79 million | -3.01 million |
| Operating Income | N/A | N/A | N/A | -2.84 million | -3.01 million |
| Income Tax Expense | N/A | N/A | N/A | N/A | N/A |
| Total Revenue | N/A | N/A | N/A | 4.1 million | 1.94 million |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | -75000 | -83000 |
| Net Income From Continuing Operations | N/A | N/A | N/A | -2.91 million | -3.1 million |
| Net Income Applicable to Common Shares | -7.11 million | -2.43 million | -5.75 million | -2.91 million | -3.1 million |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | N/A | N/A | N/A |
| Change to Liabilities | -1.1 million | 208000 | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Net Borrowings | N/A | -4.35 million | N/A | N/A | N/A |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Operating Activities | -14000 | 1.23 million | N/A | N/A | N/A |
| Change in Cash | N/A | N/A | N/A | N/A | N/A |
| Total Cash from Operating Activities | -2.66 million | -3.22 million | N/A | N/A | N/A |
| Depreciation | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | 841000 | 940000 | N/A | N/A | N/A |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | N/A | N/A | 14.6 million | 15.62 million |
| Total Stockholder Equity | N/A | N/A | N/A | 10.44 million | 11.16 million |
| Other Current Liabilities | N/A | 5 million | N/A | N/A | N/A |
| Total Assets | N/A | N/A | N/A | 25.04 million | 26.78 million |
| Common Stock | 8.76 million | 48000 | 46000 | 10.44 million | 11.16 million |
| Other Current Assets | N/A | 9000 | N/A | 1.68 million | N/A |
| Retained Earnings | N/A | -248.76 million | -246.32 million | -240.57 million | N/A |
| Other Liabilities | 9.57 million | N/A | N/A | 9.42 million | 10.47 million |
| Other Assets | 2.04 million | 360000 | 360000 | 3.75 million | 4.18 million |
| Cash | N/A | N/A | N/A | 20.93 million | 22.6 million |
| Total Current Liabilities | N/A | 8.21 million | N/A | 13.77 million | N/A |
| Other Stockholder Equity | N/A | N/A | N/A | N/A | N/A |
| Property, Plant & Equipment | N/A | 1.02 million | 1.1 million | 1.18 million | N/A |
| Total Current Assets | 17.29 million | 16.02 million | N/A | 23.51 million | 22.6 million |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 8.76 million | 8.12 million | 7.29 million | 10.44 million | 11.16 million |
| Short Term Investments | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | 5.15 million |
| Inventory | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | 909000 | N/A | 1.63 million | N/A |
Clearside Biomedical, Inc (CLSD) Chart:
Clearside Biomedical, Inc (CLSD) News:
Below you will find a list of latest news for Clearside Biomedical, Inc (CLSD) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Clearside Biomedical, Inc (CLSD) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest CLSD Trades:
Clearside Biomedical, Inc (CLSD) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-09-24 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-18 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-08-10 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-10 | 8-K (Current report) | |
| 2020-06-26 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-06-26 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 8-K (Current report) | |
| 2020-06-03 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-22 | 424B5 (Prospectus [Rule 424(b)(5)]) | |
| 2020-05-22 | EFFECT (Notice of Effectiveness) | |
| 2020-05-21 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-05-20 | CORRESP (Correspondence) | |
Clearside Biomedical, Inc (CLSD) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Clearside Biomedical, Inc (CLSD). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 830%
Institutional Ownership: 4137%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-09-22 | GEORGE M LASEZKAY | CEO | Sell | 13,411.00 | 1.59 | 21,323.49 | 302,689.00 | |
| 2020-08-18 | William D. Humphries | Director | Buy | 5,586.00 | 1.78 | 9,943.08 | 5,586.00 | |
| 2020-08-13 | BRADFORD T WHITMORE | 10% Share Holder | Buy | 50,000.00 | 1.65 | 82,560.00 | 2,950,000.00 | |
| 2020-08-12 | BRADFORD T WHITMORE | 10% Share Holder | Buy | 300,000.00 | 1.63 | 489,120.00 | 2,900,000.00 | |
| 2020-06-01 | Charles A. Deignan | Chief Financial Officer | Sell | 14,992.00 | 1.88 | 28,184.96 | 220,827.00 | |
| 2020-05-20 | Nancy J Hutson | Director | Buy | 5,000.00 | 1.85 | 9,250.00 | 5,000.00 | |
| 2020-05-12 | GEORGE M LASEZKAY | CEO | Sell | 32,150.00 | 1.99 | 63,978.50 | 311,100.00 | |
| 2020-03-11 | GEORGE M LASEZKAY | CEO | Buy | 50,000.00 | 343,250.00 | | ||
| 2020-01-08 | Charles A. Deignan | Chief Financial Officer | Buy | 25,000.00 | 228,856.00 | | ||
| 2020-01-08 | GEORGE M LASEZKAY | CEO | Buy | 66,250.00 | 288,250.00 | | ||
| 2019-11-22 | Clay Thorp | Director | Buy | 1,518,026.00 | 1.05 | 1,599,999.40 | 4,984,420.00 | |
| 2019-11-12 | Charles A. Deignan | Chief Financial Officer | Buy | 7,500.00 | 1.14 | 8,550.00 | 203,856.00 | |
| 2019-11-11 | GEORGE M LASEZKAY | CEO | Buy | 12,000.00 | 1.16 | 13,920.00 | 222,000.00 | |
| 2019-09-18 | Charles A. Deignan | Chief Financial Officer | Buy | 70,000.00 | 196,356.00 | | ||
| 2019-09-18 | GEORGE M LASEZKAY | CEO | Buy | 110,000.00 | 210,000.00 | | ||
| 2019-08-07 | GEORGE M LASEZKAY | CEO | Buy | 100,000.00 | 100,000.00 | | ||
| 2019-05-31 | Charles A. Deignan | Chief Financial Officer | Buy | 50,000.00 | 126,356.00 | | ||
| 2019-05-31 | Brion S. Raymond | Chief Commercial Officer | Buy | 50,000.00 | 50,000.00 | | ||
| 2019-03-15 | Charles A. Deignan | Chief Financial Officer | Buy | 10,000.00 | 1.36 | 13,600.00 | 76,356.00 | |
| 2018-12-06 | Clay Thorp | Director | Buy | 8,000.00 | 1.36 | 10,880.00 | 8,000.00 | |